Genetic polymorphisms of drug metabolizing enzymes and transporters: The long way from bench to bedside

Current Topics in Medicinal Chemistry

Volumn 12, Issue 15, 2012, Pages 1720-1729

  Evrard, Alexandre ^a   Mbatchi, Litaty ^a  

^a NÎMES UNIVERSITY HOSPITAL   (France)

Author keywords

Drug metabolizing enzymes and transporters; GWAS; Haplotype; Pharmacogenetics

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); AZATHIOPRINE; CAPECITABINE; CYTIDINE DEAMINASE; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DIHYDROPYRIMIDINE DEHYDROGENASE; DRUG METABOLIZING ENZYME; FIRTECAN; FIRTECAN GLUCURONIDE; FIRTECAN PEGOL; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FLUOXETINE; FOLIC ACID; FOLINIC ACID; GEMCITABINE; GLUCURONOSYLTRANSFERASE 1A1; HOMOCYSTEINE; IRINOTECAN; MERCAPTOPURINE; METHOTREXATE; PREGNANE X RECEPTOR; PRODRUG; RALTITREXED; TAMOXIFEN; THIOPURINE METHYLTRANSFERASE; THYMIDYLATE SYNTHASE; TUMOR MARKER; UFT; UNINDEXED DRUG;

ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL PRACTICE; COHORT ANALYSIS; COLORECTAL CANCER; COMPUTER PROGRAM; COST EFFECTIVENESS ANALYSIS; DEAMINATION; DIAGNOSTIC PROCEDURE; DIARRHEA; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DNA SYNTHESIS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG RESPONSE; DRUG TARGETING; DRUG TRANSFORMATION; ENZYME ACTIVATION; ENZYME DEFICIENCY; ERYTHROCYTE; FOLATE METABOLISM; GENE LOCUS; GENETIC CORRELATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; GYNECOLOGIC CANCER; HAPLOTYPE; HAPLOTYPE MAP; HEAD AND NECK CANCER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LUNG CANCER; MUCOSA INFLAMMATION; NEUTROPENIA; NONHODGKIN LYMPHOMA; PANCREAS CANCER; PHARMACOGENETICS; PHENOTYPE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCREENING; SINGLE NUCLEOTIDE POLYMORPHISM; SPECTROPHOTOMETRY; TREATMENT OUTCOME;

CARRIER PROTEINS; ENZYMES; GENETIC MARKERS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84867563727     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612803531388     Document Type: Article

References (128)

1. Kalow, W.; Staron, N. On distribution and inheritance of atypical forms of human serum cholinesterase, as indicated by dibucaine numbers. Can. J. Biochem Physiol., 1957, 35(12), 1305-1320.
2. Motulsky, A.G. Drug reactions enzymes, and biochemical genetics. J. Am. Med. Assoc., 1957, 165(7), 835-837.
3. Bertilsson, L.; Mellstrom, B.; Sjokvist, F.; Martenson, B.; Asberg, M. Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet, 1981, 1(8219), 560-561.
4. Mahgoub, A.; Idle, J. R.; Dring, L. G.; Lancaster, R.; Smith, R. L. Polymorphic hydroxylation of Debrisoquine in man. Lancet, 1977, 2(8038), 584-586.
5. Walko, C. M.; McLeod, H. Pharmacogenomic progress in individualized dosing of key drugs for cancer patients. Nat. Clin. Pract. Oncol., 2009, 6(3), 153-162.
6. Ciccolini, J.; Mercier, C.; Dahan, L.; Andre, N. Integrating pharmacogenetics into gemcitabine dosing--time for a change? Nat. Rev. Clin. Oncol., 2011, 8(7), 439-444.
7. Zhang, B.; Xie, W.; Krasowski, M. D. PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics, 2008, 9(11), 1695-1709.
8. Deloukas, P.; Bentley, D. The HapMap project and its application to genetic studies of drug response. Pharmacogenomics J, 2004, 4(2), 88-90.
9. Relling, M. V.; Yanishevski, Y.; Nemec, J.; Evans, W. E.; Boyett, J. M.; Behm, F. G.; Pui, C. H. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia, 1998, 12(3), 346-352.
10. Oselin, K.; Anier, K.; Tamm, R.; Kallassalu, K.; Maeorg, U. Determination of thiopurine S-methyltransferase (TPMT) activity by comparing various normalization factors: reference values for Estonian population using HPLC-UV assay. J Chromatogr B Analyt Technol Biomed Life Sci, 2006, 834(1-2), 77-83.
11. Schaeffeler, E.; Eichelbaum, M.; Reinisch, W.; Zanger, U. M.; Schwab, M. Three novel thiopurine S-methyltransferase allelic variants (TPMT*20, *21, *22) - association with decreased enzyme function. Hum. Mutat., 2006, 27(9), 976.
12. Garat, A.; Cauffiez, C.; Renault, N.; Lo-Guidice, J. M.; Allorge, D.; Chevalier, D.; Houdret, N.; Chavatte, P.; Loriot, M. A.; Gala, J. L.; Broly, F. Characterisation of novel defective thiopurine Smethyltransferase allelic variants. Biochem Pharmacol, 2008, 76(3), 404-415.
13. Ujiie, S.; Sasaki, T.; Mizugaki, M.; Ishikawa, M.; Hiratsuka, M. Functional characterization of 23 allelic variants of thiopurine Smethyltransferase gene (TPMT*2 - *24). Pharmacogenet Genomics, 2008, 18(10), 887-893.
14. Bergan, S.; Rugstad, H. E.; Bentdal, O.; Stokke, O. Monitoring of azathioprine treatment by determination of 6-thioguanine nucleotide concentrations in erythrocytes. Transplantation, 1994, 58(7), 803-808.
15. Armstrong, V. W.; Shipkova, M.; von Ahsen, N.; Oellerich, M. Analytic aspects of monitoring therapy with thiopurine medications. Ther Drug Monit, 2004, 26(2), 220-226.
16. Relling, M. V.; Gardner, E. E.; Sandborn, W. J.; Schmiegelow, K.; Pui, C. H.; Yee, S. W.; Stein, C. M.; Carrillo, M.; Evans, W. E.; Klein, T. E. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther., 89(3), 387-391.
17. Wang, L.; Weinshilboum, R. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene, 2006, 25(11), 1629-1638.
18. Diasio, R. B. The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. Oncology (Williston Park), 1998, 12(10 Suppl 7), 23-27.
19. Harris, B. E.; Carpenter, J. T.; Diasio, R. B. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer, 1991, 68(3), 499-501.
20. Wei, X.; McLeod, H. L.; McMurrough, J.; Gonzalez, F. J.; Fernandez-Salguero, P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J. Clin. Invest., 1996, 98(3), 610-615.
21. Milano, G.; Etienne, M. C.; Pierrefite, V.; Barberi-Heyob, M.; Deporte-Fety, R.; Renee, N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br. J. Cancer, 1999, 79(3-4), 627-630.
22. Ciccolini, J.; Mercier, C.; Blachon, M. F.; Favre, R.; Durand, A.; Lacarelle, B. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity. J. Clin. Pharm. Ther., 2004, 29(4), 307-315.
23. Deporte-Fety, R.; Picot, M.; Amiand, M.; Moreau, A.; Campion, L.; Lanoe, D.; Renee, N.; Milano, G. High-performance liquid chromatographic assay with ultraviolet detection for quantification of dihydrofluorouracil in human lymphocytes: application to measurement of dihydropyrimidine dehydrogenase activity. J. Chromatogr. B. Biomed. Sci. Appl., 2001, 762(2), 203-209.
24. Boisdron-Celle, M.; Remaud, G.; Traore, S.; Poirier, A. L.; Gamelin, L.; Morel, A.; Gamelin, E. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett, 2007, 249(2), 271-282.
25. Yokota, H.; Fernandez-Salguero, P.; Furuya, H.; Lin, K.; McBride, O.W.; Podschun, B.; Schnackerz, K.D.; Gonzalez, F.J. cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria. J. Biol. Chem., 1994, 269(37), 23192-23196.
26. Raida, M.; Schwabe, W.; Hausler, P.; Van Kuilenburg, A.B.; Van Gennip, A.H.; Behnke, D.; Hoffken, K. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin. Cancer Res., 2001, 7(9), 2832-2839.
27. Van Kuilenburg, A.B.; Meinsma, R.; Zoetekouw, L.; Van Gennip, A.H. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5- fluorouracil-associated toxicity. Pharmacogenetics, 2002, 12(7), 555-558.
28. Deenen, M.J.; Tol, J.; Burylo, A.M.; Doodeman, V.D.; de Boer, A.; Vincent, A.; Guchelaar, H.J.; Smits, P.H.; Beijnen, J.H.; Punt, C.J.; Schellens, J.H.; Cats, A. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin. Cancer Res., 2011, 17(10), 3455-3468.
29. Amstutz, U.; Farese, S.; Aebi, S.; Largiader, C.R. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. Pharmacogenomics, 2009, 10(6), 931-944.
30. Ezzeldin, H.H.; Lee, A.M.; Mattison, L.K.; Diasio, R.B. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin. Cancer Res., 2005, 11(24 Pt 1), 8699-8705.
31. Hirota, T.; Date, Y.; Nishibatake, Y.; Takane, H.; Fukuoka, Y.; Taniguchi, Y.; Burioka, N.; Shimizu, E.; Nakamura, H.; Otsubo, K.; Ieiri, I. Dihydropyrimidine dehydrogenase (DPD) expression is negatively regulated by certain microRNAs in human lung tissues. Lung Cancer, 2012.
32. Danenberg, P.V. Pharmacogenomics of thymidylate synthase in cancer treatment. Front. Biosci., 2004, 9, 2484-2494.
33. Mandola, M.V.; Stoehlmacher, J.; Zhang, W.; Groshen, S.; Yu, M.C.; Iqbal, S.; Lenz, H.J.; Ladner, R.D.A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics, 2004, 14(5), 319-327.
34. Afzal, S.; Gusella, M.; Jensen, S.A.; Vainer, B.; Vogel, U.; Andersen, J.T.; Brodbaek, K.; Petersen, M.; Jimenez-Solem, E.; Adleff, V.; Budai, B.; Hitre, E.; Lang, I.; Orosz, E.; Bertolaso, L.; Barile, C.; Padrini, R.; Kralovanszky, J.; Pasini, F.; Poulsen, H.E. The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer. Pharmacogenomics, 2011, 12(9), 1257-1267.
35. Largillier, R.; Etienne-Grimaldi, M.C.; Formento, J.L.; Ciccolini, J.; Nebbia, J.F.; Ginot, A.; Francoual, M.; Renee, N.; Ferrero, J.M.; Foa, C.; Namer, M.; Lacarelle, B.; Milano, G. Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin. Cancer Res., 2006, 12(18), 5496-5502.
36. De Mattia, E.; Toffoli, G. C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur. J. Cancer, 2009, 45(8), 1333-1351.
37. Toffoli, G.; De Mattia, E. Pharmacogenetic relevance of MTHFR polymorphisms. Pharmacogenomics, 2008, 9(9), 1195-1206.
38. Fisher, M.C.; Cronstein, B.N. Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J. Rheumatol., 2009, 36(3), 539-545.
39. Lopez-Lopez, E.; Ballesteros, J.; Garcia-Orad, A. MTHFR 677TT genotype and toxicity of methotrexate: controversial results. Cancer Chemother. Pharmacol, 2011, 68(5), 1369-1370; author reply 1371.
40. Ulrich, C.M.; Yasui, Y.; Storb, R.; Schubert, M.M.; Wagner, J.L.; Bigler, J.; Ariail, K.S.; Keener, C. L.; Li, S.; Liu, H.; Farin, F.M.; Potter, J.D. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood, 2001, 98(1), 231-234.
41. Afzal, S.; Jensen, S.A.; Vainer, B.; Vogel, U.; Matsen, J.P.; Sorensen, J.B.; Andersen, P.K.; Poulsen, H.E. MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer. Ann. Oncol., 2009, 20(10), 1660-1666.
42. Boige, V.; Mendiboure, J.; Pignon, J.P.; Loriot, M.A.; Castaing, M.; Barrois, M.; Malka, D.; Tregouet, D.A.; Bouche, O.; Le Corre, D.; Miran, I.; Mulot, C.; Ducreux, M.; Beaune, P.; Laurent-Puig, P. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J. Clin. Oncol., 2010, 28(15), 2556-2564.
43. Etienne, M.C.; Formento, J.L.; Chazal, M.; Francoual, M.; Magne, N.; Formento, P.; Bourgeon, A.; Seitz, J.F.; Delpero, J.R.; Letoublon, C.; Pezet, D.; Milano, G. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics, 2004, 14(12), 785-792.
44. Etienne-Grimaldi, M.C.; Milano, G.; Maindrault-Goebel, F.; Chibaudel, B.; Formento, J.L.; Francoual, M.; Lledo, G.; Andre, T.; Mabro, M.; Mineur, L.; Flesch, M.; Carola, E.; de Gramont, A. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br. J. Clin. Pharmacol., 2010, 69(1), 58-66.
45. Kadakol, A.; Ghosh, S.S.; Sappal, B.S.; Sharma, G.; Chowdhury, J.R.; Chowdhury, N.R. Genetic lesions of bilirubin uridinediphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype. Hum. Mutat., 2000, 16(4), 297-306.
46. Mathijssen, R.H.; van Alphen, R.J.; Verweij, J.; Loos, W.J.; Nooter, K.; Stoter, G.; Sparreboom, A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res., 2001, 7(8), 2182-2194.
47. Cote, J.F.; Kirzin, S.; Kramar, A.; Mosnier, J.F.; Diebold, M.D.; Soubeyran, I.; Thirouard, A.S.; Selves, J.; Laurent-Puig, P.; Ychou, M. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin. Cancer Res., 2007, 13(11), 3269-3275.
48. Rouits, E.; Boisdron-Celle, M.; Dumont, A.; Guerin, O.; Morel, A.; Gamelin, E. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin. Cancer Res., 2004, 10(15), 5151-5159.
49. Toffoli, G.; Cecchin, E. Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolateand fluoropyrimidine-based chemotherapy. J. Chemother., 2004, 16 Suppl 4, 31-35.
50. Ma, M.K.; McLeod, H.L. Lessons learned from the irinotecan metabolic pathway. Curr. Med. Chem., 2003, 10(1), 41-49.
51. Hoskins, J.M.; Goldberg, R.M.; Qu, P.; Ibrahim, J.G.; McLeod, H.L. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J. Natl. Cancer Inst., 2007, 99(17), 1290-1295.
52. Mathijssen, R.H.; Gurney, H. Irinogenetics: how many stars are there in the sky? J. Clin. Oncol., 2009, 27(16), 2578-2579.
53. Kim, T.W.; Innocenti, F. Insights, challenges, and future directions in irinogenetics. Ther. Drug Monit, 2007, 29(3), 265-270.
54. Innocenti, F.; Vokes, E.E.; Ratain, M.J. Irinogenetics: what is the right star? J. Clin. Oncol., 2006, 24(15), 2221-2224.
55. Innocenti, F.; Ratain, M.J. Irinogenetics and UGT1A: from genotypes to haplotypes. Clin. Pharmacol. Ther., 2004, 75(6), 495-500.
56. Raynal, C.; Pascussi, J.M.; Leguelinel, G.; Breuker, C.; Kantar, J.; Lallemant, B.; Poujol, S.; Bonnans, C.; Joubert, D.; Hollande, F.; Lumbroso, S.; Brouillet, J. P.; Evrard, A. Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation. Mol. Cancer, 2010, 9, 46.
57. Sugatani, J.; Mizushima, K.; Osabe, M.; Yamakawa, K.; Kakizaki, S.; Takagi, H.; Mori, M.; Ikari, A.; Miwa, M. Transcriptional regulation of human UGT1A1 gene expression through distal and proximal promoter motifs: implication of defects in the UGT1A1 gene promoter. Naunyn Schmiedebergs Arch Pharmacol., 2008, 377(4-6), 597-605.
58. Mannel, M. Drug interactions with St John's wort: mechanisms and clinical implications. Drug Saf., 2004, 27(11), 773-797.
59. Bardia, A.; Stearns, V. Personalized tamoxifen: a step closer but miles to go. Clin. Cancer Res., 2010, 16(17), 4308-4310.
60. Henry, N.L.; Hayes, D.F.; Rae, J.M. CYP2D6 testing for breast cancer patients: is there more to the story? Oncology (Williston Park), 2009, 23(14), 1236, 1243-1249.
61. Goetz, M.P. Tamoxifen, endoxifen, and CYP2D6: the rules for evaluating a predictive factor. Oncology (Williston Park), 2009, 23(14), 1233-4, 1236.
62. Garber, K. Tamoxifen pharmacogenetics moves closer to reality. J. Natl. Cancer Inst., 2005, 97(6), 412-413.
63. Yu, K.D.; Shao, Z.M. Genetic matters of CYP2D6 in breast cancer: copy number variations and nucleotide polymorphisms. Nat. Rev. Cancer, 2009, 9(11), 842.
64. Kiyotani, K.; Mushiroda, T.; Imamura, C.K.; Hosono, N.; Tsunoda, T.; Kubo, M.; Tanigawara, Y.; Flockhart, D.A.; Desta, Z.; Skaar, T.C.; Aki, F.; Hirata, K.; Takatsuka, Y.; Okazaki, M.; Ohsumi, S.; Yamakawa, T.; Sasa, M.; Nakamura, Y.; Zembutsu, H. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J. Clin. Oncol., 2010, 28(8), 1287-1293.
65. Schroth, W.; Goetz, M.P.; Hamann, U.; Fasching, P.A.; Schmidt, M.; Winter, S.; Fritz, P.; Simon, W.; Suman, V.J.; Ames, M.M.; Safgren, S.L.; Kuffel, M.J.; Ulmer, H.U.; Bolander, J.; Strick, R.; Beckmann, M.W.; Koelbl, H.; Weinshilboum, R.M.; Ingle, J.N.; Eichelbaum, M.; Schwab, M.; Brauch, H. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA, 2009, 302(13), 1429-1436.
66. Goetz, M.P.; Rae, J.M.; Suman, V.J.; Safgren, S.L.; Ames, M.M.; Visscher, D.W.; Reynolds, C.; Couch, F.J.; Lingle, W.L.; Flockhart, D.A.; Desta, Z.; Perez, E.A.; Ingle, J.N. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol., 2005, 23(36), 9312-9318.
67. Schroth, W.; Hamann, U.; Fasching, P.A.; Dauser, S.; Winter, S.; Eichelbaum, M.; Schwab, M.; Brauch, H. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin. Cancer Res., 2010, 16(17), 4468-4477.
68. Kuderer, N.M.; Peppercorn, J. CYP2D6 testing in breast cancer: ready for prime time? Oncology (Williston Park), 2009, 23(14), 1223-1232.
69. Gjerde, J.; Hauglid, M.; Breilid, H.; Lundgren, S.; Varhaug, J.E.; Kisanga, E.R.; Mellgren, G.; Steen, V.M.; Lien, E.A. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann. Oncol., 2008, 19(1), 56-61.
70. Jin, Y.; Desta, Z.; Stearns, V.; Ward, B.; Ho, H.; Lee, K.H.; Skaar, T.; Storniolo, A.M.; Li, L.; Araba, A.; Blanchard, R.; Nguyen, A.; Ullmer, L.; Hayden, J.; Lemler, S.; Weinshilboum, R.M.; Rae, J.M.; Hayes, D.F.; Flockhart, D.A. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl. Cancer Inst., 2005, 97(1), 30-39.
71. de Graan, A.J.; Teunissen, S.F.; de Vos, F.Y.; Loos, W.J.; van Schaik, R.H.; de Jongh, F.E.; de Vos, A.I.; van Alphen, R.J.; van der Holt, B.; Verweij, J.; Seynaeve, C.; Beijnen, J.H.; Mathijssen, R.H. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. J. Clin. Oncol., 2011, 29(24), 3240-3246.
72. Mini, E.; Nobili, S.; Caciagli, B.; Landini, I.; Mazzei, T. Cellular pharmacology of gemcitabine. Ann. Oncol., 2006, 17 Suppl 5, v7-12.
73. Gupta, N.; Ahmed, I.; Steinberg, H.; Patel, D.; Nissel-Horowitz, S.; Mehrotra, B. Gemcitabine-induced pulmonary toxicity: case report and review of the literature. Am. J. Clin. Oncol., 2002, 25(1), 96-100.
74. Yonemori, K.; Ueno, H.; Okusaka, T.; Yamamoto, N.; Ikeda, M.; Saijo, N.; Yoshida, T.; Ishii, H.; Furuse, J.; Sugiyama, E.; Kim, S.R.; Kikura-Hanajiri, R.; Hasegawa, R.; Saito, Y.; Ozawa, S.; Kaniwa, N.; Sawada, J. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin. Cancer Res., 2005, 11(7), 2620-2624.
75. Mercier, C.; Raynal, C.; Dahan, L.; Ortiz, A.; Evrard, A.; Dupuis, C.; Blesius, A.; Duluc, M.; Franceschini, F.; Giacometti, S.; Salas, S.; Milano, G.; Favre, R.; Seitz, J. F.; Ciccolini, J. Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. Pharmacogenet. Genomics, 2007, 17(10), 841-844.
76. Maring, J.G.; Wachters, F.M.; Slijfer, M.; Maurer, J.M.; Boezen, H.M.; Uges, D.R.; de Vries, E.G.; Groen, H.J. Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. Eur. J. Clin. Pharmacol., 2010, 66(6), 611-617.
77. Sugiyama, E.; Kaniwa, N.; Kim, S.R.; Kikura-Hanajiri, R.; Hasegawa, R.; Maekawa, K.; Saito, Y.; Ozawa, S.; Sawada, J.; Kamatani, N.; Furuse, J.; Ishii, H.; Yoshida, T.; Ueno, H.; Okusaka, T.; Saijo, N. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J. Clin. Oncol., 2007, 25(1), 32-42.
78. Ueno, H.; Kaniwa, N.; Okusaka, T.; Ikeda, M.; Morizane, C.; Kondo, S.; Sugiyama, E.; Kim, S.R.; Hasegawa, R.; Saito, Y.; Yoshida, T.; Saijo, N.; Sawada, J. Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients. Br. J. Cancer, 2009, 100(6), 870-873.
79. Mercier, C.; Evrard, A.; Ciccolini, J. Genotype-based methods for anticipating gemcitabine-related severe toxicities may lead to falsenegative results. J. Clin. Oncol., 2007, 25(30), 4855; author reply 4855-6.
80. Raynal, C.; Ciccolini, J.; Mercier, C.; Boyer, J.C.; Polge, A.; Lallemant, B.; Mouzat, K.; Lumbroso, S.; Brouillet, J.P.; Evrard, A. High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabine. Ther. Drug Monit., 2010, 32(1), 53-60.
81. Ciccolini, J.; Dahan, L.; Andre, N.; Evrard, A.; Duluc, M.; Blesius, A.; Yang, C.; Giacometti, S.; Brunet, C.; Raynal, C.; Ortiz, A.; Frances, N.; Iliadis, A.; Duffaud, F.; Seitz, J.F.; Mercier, C. Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. J. Clin. Oncol., 2010, 28(1), 160-165.
82. Mercier, C.; Dupuis, C.; Blesius, A.; Fanciullino, R.; Yang, C.G.; Padovani, L.; Giacometti, S.; Frances, N.; Iliadis, A.; Duffaud, F.; Ciccolini, J. Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile. Cancer Chemother. Pharmacol., 2009, 63(6), 1177-1180.
83. Caronia, D.; Martin, M.; Sastre, J.; de la Torre, J.; Garcia-Saenz, J. A.; Alonso, M. R.; Moreno, L. T.; Pita, G.; Diaz-Rubio, E.; Benitez, J.; Gonzalez-Neira, A. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced handfoot syndrome. Clin. Cancer Res., 2011, 17(7), 2006-2013.
84. Bertilsson, G.; Heidrich, J.; Svensson, K.; Asman, M.; Jendeberg, L.; Sydow-Backman, M.; Ohlsson, R.; Postlind, H.; Blomquist, P.; Berkenstam, A. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc. Natl. Acad. Sci. U S A, 1998, 95(21), 12208-12213.
85. Kliewer, S.A.; Goodwin, B.; Willson, T.M. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr. Rev., 2002, 23(5), 687-702.
86. Willson, T.M.; Kliewer, S.A. PXR, CAR and drug metabolism. Nat. Rev. Drug Discov., 2002, 1(4), 259-266.
87. Vyhlidal, C.A.; Rogan, P.K.; Leeder, J.S. Development and refinement of pregnane X receptor (PXR) DNA binding site model using information theory: insights into PXR-mediated gene regulation. J. Biol. Chem., 2004, 279(45), 46779-46786.
88. Koyano, S.; Kurose, K.; Ozawa, S.; Saeki, M.; Nakajima, Y.; Hasegawa, R.; Komamura, K.; Ueno, K.; Kamakura, S.; Nakajima, T.; Saito, H.; Kimura, H.; Goto, Y.; Saitoh, O.; Katoh, M.; Ohnuma, T.; Kawai, M.; Sugai, K.; Ohtsuki, T.; Suzuki, C.; Minami, N.; Saito, Y.; Sawada, J. Eleven novel single nucleotide polymorphisms in the NR1I2 (PXR) gene, four of which induce nonsynonymous amino acid alterations. Drug Metab. Pharmacokinet., 2002, 17(6), 561-565.
89. Gardner-Stephen, D.; Heydel, J.M.; Goyal, A.; Lu, Y.; Xie, W.; Lindblom, T.; Mackenzie, P.; Radominska-Pandya, A. Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression. Drug Metab. Dispos., 2004, 32(3), 340-347.
90. Lamba, J.; Lamba, V.; Schuetz, E. Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr. Drug Metab., 2005, 6(4), 369-383.
91. Forman, B.M. Polymorphisms in promiscuous PXR: an explanation for interindividual differences in drug clearance? Pharmacogenetics, 2001, 11(7), 551-552.
92. Ma, X.; Idle, J.R.; Gonzalez, F.J. The pregnane X receptor: from bench to bedside. Expert Opin. Drug Metab. Toxicol., 2008, 4(7), 895-908.
93. Hustert, E.; Zibat, A.; Presecan-Siedel, E.; Eiselt, R.; Mueller, R.; Fuss, C.; Brehm, I.; Brinkmann, U.; Eichelbaum, M.; Wojnowski, L.; Burk, O. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab. Dispos., 2001, 29(11), 1454-1459.
94. Koyano, S.; Kurose, K.; Saito, Y.; Ozawa, S.; Hasegawa, R.; Komamura, K.; Ueno, K.; Kamakura, S.; Kitakaze, M.; Nakajima, T.; Matsumoto, K.; Akasawa, A.; Saito, H.; Sawada, J. Functional characterization of four naturally occurring variants of human pregnane X receptor (PXR): one variant causes dramatic loss of both DNA binding activity and the transactivation of the CYP3A4 promoter/enhancer region. Drug Metab. Dispos., 2004, 32(1), 149-154.
95. Lamba, J.; Lamba, V.; Strom, S.; Venkataramanan, R.; Schuetz, E. Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab. Dispos., 2008, 36(1), 169-181.
96. Zhang, J.; Kuehl, P.; Green, E.D.; Touchman, J.W.; Watkins, P.B.; Daly, A.; Hall, S.D.; Maurel, P.; Relling, M.; Brimer, C.; Yasuda, K.; Wrighton, S.A.; Hancock, M.; Kim, R.B.; Strom, S.; Thummel, K.; Russell, C.G.; Hudson, J.R., Jr.; Schuetz, E.G.; Boguski, M.S. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics, 2001, 11(7), 555-572.
97. Xu, C.F.; Bing, N.X.; Ball, H.A.; Rajagopalan, D.; Sternberg, C.N.; Hutson, T.E.; de Souza, P.; Xue, Z.G.; McCann, L.; King, K.S.; Ragone, L.J.; Whittaker, J.C.; Spraggs, C.F.; Cardon, L.R.; Mooser, V.E.; Pandite, L.N. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesisrelated and exposure-related genes. J. Clin. Oncol., 2011, 29(18), 2557-2564.
98. Garcia-Donas, J.; Esteban, E.; Leandro-Garcia, L.J.; Castellano, D.E.; del Alba, A.G.; Climent, M.A.; Arranz, J.A.; Gallardo, E.; Puente, J.; Bellmunt, J.; Mellado, B.; Martinez, E.; Moreno, F.; Font, A.; Robledo, M.; Rodriguez-Antona, C. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol., 2011, 12(12), 1143-1150.
99. Klumpen, H.J.; Samer, C.F.; Mathijssen, R.H.; Schellens, J.H.; Gurney, H. Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treat. Rev., 2011, 37(4), 251-260.
100. Oleson, L.; von Moltke, L.L.; Greenblatt, D.J.; Court, M.H. Identification of polymorphisms in the 3'-untranslated region of the human pregnane X receptor (PXR) gene associated with variability in cytochrome P450 3A (CYP3A) metabolism. Xenobiotica, 2010, 40(2), 146-162.
101. Sandanaraj, E.; Lal, S.; Selvarajan, V.; Ooi, L.L.; Wong, Z.W.; Wong, N.S.; Ang, P.C.; Lee, E.J.; Chowbay, B. PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients. Clin. Cancer Res., 2008, 14(21), 7116-7126.
102. Schipani, A.; Siccardi, M.; D'Avolio, A.; Baietto, L.; Simiele, M.; Bonora, S.; Rodriguez Novoa, S.; Cuenca, L.; Soriano, V.; Chierakul, N.; Saguenwong, N.; Chuchuttaworn, C.; Hoskins, J.M.; Dvorak, A.M.; McLeod, H.L.; Davies, G.; Khoo, S.; Back, D.J.; Di Perri, G.; Owen, A. Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob. Agents Chemother., 2010, 54(12), 5242-5250.
103. Siccardi, M.; D'Avolio, A.; Baietto, L.; Gibbons, S.; Sciandra, M.; Colucci, D.; Bonora, S.; Khoo, S.; Back, D. J.; Di Perri, G.; Owen, A. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir. Clin. Infect. Dis., 2008, 47(9), 1222-1225.
104. Daly, M.J.; Rioux, J.D.; Schaffner, S.F.; Hudson, T.J.; Lander, E.S. High-resolution haplotype structure in the human genome. Nat. Genet., 2001, 29(2), 229-232.
105. Reich, D.E.; Cargill, M.; Bolk, S.; Ireland, J.; Sabeti, P.C.; Richter, D.J.; Lavery, T.; Kouyoumjian, R.; Farhadian, S.F.; Ward, R.; Lander, E.S. Linkage disequilibrium in the human genome. Nature, 2001, 411(6834), 199-204.
106. Chew, S.C.; Sandanaraj, E.; Singh, O.; Chen, X.; Tan, E.H.; Lim, W.T.; Lee, E.J.; Chowbay, B. Influence of SLCO1B3 haplotypetag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients. Br. J. Clin. Pharmacol., 2012, 73(4), 606-618.
107. Barrett, J.C.; Fry, B.; Maller, J.; Daly, M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics, 2005, 21(2), 263-265.
108. The International Hap Map Project. Nature, 2003, 426(6968), 789796.
109. Comets, E.; Verstuyft, C.; Lavielle, M.; Jaillon, P.; Becquemont, L.; Mentre, F. Modelling the influence of MDR1 polymorphism on digoxin pharmacokinetic parameters. Eur. J. Clin. Pharmacol., 2007, 63(5), 437-449.
110. Clark, A.G. Inference of haplotypes from PCR-amplified samples of diploid populations. Mol. Biol. Evol., 1990, 7(2), 111-122.
111. Niu, T.; Qin, Z.S.; Xu, X.; Liu, J.S. Bayesian haplotype inference for multiple linked single-nucleotide polymorphisms. Am. J. Hum. Genet., 2002, 70(1), 157-169.
112. Stephens, M.; Smith, N.J.; Donnelly, P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet., 2001, 68(4), 978-989.
113. Excoffier, L.; Slatkin, M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol. Biol. Evol., 1995, 12(5), 921-927.
114. Shi, Y.Y.; He, L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res., 2005, 15(2), 97-98.
115. Gonzalez, J.R.; Armengol, L.; Sole, X.; Guino, E.; Mercader, J.M.; Estivill, X.; Moreno, V. SNPassoc: an R package to perform whole genome association studies. Bioinformatics, 2007, 23(5), 644-645.
116. Purcell, S.; Neale, B.; Todd-Brown, K.; Thomas, L.; Ferreira, M.A.; Bender, D.; Maller, J.; Sklar, P.; de Bakker, P.I.; Daly, M.J.; Sham, P.C. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet., 2007, 81(3), 559-575.
117. Tregouet, D.A.; Garelle, V. A new JAVA interface implementation of THESIAS: testing haplotype effects in association studies. Bioinformatics, 2007, 23(8), 1038-1039.
118. Carter, K.W.; McCaskie, P.A.; Palmer, L.J. SimHap GUI: an intuitive graphical user interface for genetic association analysis. BMC Bioinformatics, 2008, 9, 557.
119. Burmester, J.K.; Sedova, M.; Shapero, M.H.; Mansfield, E. DMET microarray technology for pharmacogenomics-based personalized medicine. Methods Mol. Biol., 2010, 632, 99-124.
120. Feng, J.; Sun, J.; Wang, M.Z.; Zhang, Z.; Kim, S.T.; Zhu, Y.; Xu, J. Compilation of a comprehensive gene panel for systematic assessment of genes that govern an individual's drug responses. Pharmacogenomics, 2010, 11(10), 1403-1425.
121. Rai, A.J.; Yee, J.; Fleisher, M. Biomarkers in the era of personalized medicine - a multiplexed SNP assay using capillary electrophoresis for assessing drug metabolism capacity. Scand. J. Clin. Lab. Invest., 2010, 242, 15-18.
122. Welch, R.A.; Lazaruk, K.; Haque, K.A.; Hyland, F.; Xiao, N.; Wronka, L.; Burdett, L.; Chanock, S. J.; Ingber, D.; De La Vega, F.M.; Yeager, M. Validation of the performance of a comprehensive genotyping assay panel of single nucleotide polymorphisms in drug metabolism enzyme genes. Hum. Mutat., 2008, 29(5), 750-756.
123. Adkins, D.E.; Aberg, K.; McClay, J.L.; Bukszar, J.; Zhao, Z.; Jia, P.; Stroup, T.S.; Perkins, D.; McEvoy, J.P.; Lieberman, J.A.; Sullivan, P.F.; van den Oord, E.J. Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol. Psychiatry, 2011, 16(3), 321-332.
124. Gamazon, E.R.; Huang, R.S.; Cox, N.J.; Dolan, M.E. Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc. Natl. Acad. Sci. U S A, 2010, 107(20), 9287-9292.
125. Ingle, J.N.; Schaid, D.J.; Goss, P.E.; Liu, M.; Mushiroda, T.; Chapman, J.A.; Kubo, M.; Jenkins, G. D.; Batzler, A.; Shepherd, L.; Pater, J.; Wang, L.; Ellis, M.J.; Stearns, V.; Rohrer, D.C.; Goetz, M.P.; Pritchard, K.I.; Flockhart, D.A.; Nakamura, Y.; Weinshilboum, R.M. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J. Clin. Oncol., 2010, 28(31), 4674-4682.
126. Murphy, A.; Lasky-Su, J.; Tantisira, K.G.; Litonjua, A.A.; Lange, C.; Weiss, S.T. Genome-wide association studies of family data in pharmacogenetics: a case study. Curr. Pharm. Des., 2009, 15(32), 3764-3772.
127. Takeuchi, F.; McGinnis, R.; Bourgeois, S.; Barnes, C.; Eriksson, N.; Soranzo, N.; Whittaker, P.; Ranganath, V.; Kumanduri, V.; McLaren, W.; Holm, L.; Lindh, J.; Rane, A.; Wadelius, M.; Deloukas, P. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet., 2009, 5(3), e1000433.
128. Liu, M.; Wang, L.; Bongartz, T.; Hawse, J.R.; Markovic, S.N.; Schaid, D.J.; Mushiroda, T.; Kubo, M.; Nakamura, Y.; Kamatani, N.; Goss, P.E.; Ingle, J.N.; Weinshilboum, R.M. Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression. Breast Cancer Res., 2012, 14(2), R41.